Form 8-K - Current report:
SEC Accession No. 0001193125-24-202430
Filing Date
2024-08-19
Accepted
2024-08-19 06:04:59
Documents
18
Period of Report
2024-08-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d879523d8k.htm   iXBRL 8-K 46711
2 EX-3.1 d879523dex31.htm EX-3.1 29306
3 EX-4.1 d879523dex41.htm EX-4.1 273386
4 EX-99.1 d879523dex991.htm EX-99.1 9800
9 GRAPHIC g879523g0818100647176.jpg GRAPHIC 3203
  Complete submission text file 0001193125-24-202430.txt   617980

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA antx-20240815.xsd EX-101.SCH 3901
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE antx-20240815_def.xml EX-101.DEF 14522
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20240815_lab.xml EX-101.LAB 24170
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20240815_pre.xml EX-101.PRE 15620
20 EXTRACTED XBRL INSTANCE DOCUMENT d879523d8k_htm.xml XML 6059
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 241218175
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)